Caplin Point Laboratories Limited — Irbesartan Exporter Profile
Indian Pharmaceutical Exporter · #3 for Irbesartan · $5.3M export value · DGFT Verified
Caplin Point Laboratories Limited is the #3 Indian exporter of Irbesartan with $5.3M in export value and 106 verified shipments. Caplin Point Laboratories Limited holds a 5.0% market share in Irbesartan exports across 9 countries. The company exports 55 pharmaceutical products worth $174.5M across 20 therapeutic categories.
Caplin Point Laboratories Limited — Irbesartan Export Profile: Buyers & Destinations
Where Does Caplin Point Laboratories Limited Export Irbesartan?
| Country | Value | Shipments | Share |
|---|---|---|---|
| GAUTEMALA | $1.1M | 40 | 36.1% |
| GUATEMALA | $782.1K | 18 | 24.8% |
| NICARAGUA | $737.5K | 24 | 23.3% |
| HONDURAS | $281.3K | 11 | 8.9% |
| EL SALVADOR | $96.4K | 3 | 3.1% |
| MALI | $67.8K | 3 | 2.1% |
| PERU | $34.1K | 1 | 1.1% |
| DOMINICAN REPULIC | $8.8K | 4 | 0.3% |
| ECUADOR | $5.5K | 1 | 0.2% |
| TURKMENISTAN | $5.1K | 1 | 0.2% |
Caplin Point Laboratories Limited exports Irbesartan to 10 countries. The largest destination is GAUTEMALA accounting for 36.1% of Caplin Point Laboratories Limited's Irbesartan shipments, followed by GUATEMALA (24.8%) and NICARAGUA (23.3%). These destinations reflect Caplin Point Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Irbesartan from Caplin Point Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NUEVOS ETICOS NEOETHICALS, S.A. | GAUTEMALA | $1.1M | 35 |
| FARMA SOLUTION SOCIEDAD ANONIMA | GUATEMALA | $493.0K | 12 |
| NEOETHICALS, S.A, | NICARAGUA | $360.9K | 12 |
| NUEVOS ETICOS NEOETHICALS S A | GAUTEMALA | $296.8K | 8 |
| NEOETHICALS S A | NICARAGUA | $237.1K | 7 |
| DROGUERIA SAIMED DE HONDURAS | HONDURAS | $188.8K | 7 |
| NUEVOS ETICOS NEOETHICALS S.A. | HONDURAS | $167.2K | 7 |
| NEOETHICALS, S.A | NICARAGUA | $134.4K | 4 |
| PHARMA PLUS MALI, S.A. | MALI | $44.3K | 1 |
| DROGUERIA SAIMED S.A. DE C.V., | EL SALVADOR | $41.2K | 1 |
Caplin Point Laboratories Limited supplies Irbesartan to 19 buyers globally. The largest buyer is NUEVOS ETICOS NEOETHICALS, S.A. (GAUTEMALA), followed by FARMA SOLUTION SOCIEDAD ANONIMA (GUATEMALA) and NEOETHICALS, S.A, (NICARAGUA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Irbesartan Export Value and How Much Does Caplin Point Laboratories Limited Contribute?
India exported $58.2M worth of Irbesartan through 2,669 shipments from 123 suppliers to 68 countries, serving 366 buyers globally. Caplin Point Laboratories Limited contributes $5.3M to this total, accounting for 5.0% of India's Irbesartan exports. Caplin Point Laboratories Limited ships Irbesartan to 10 countries through 19 buyers.
What Is the Average Shipment Value for Caplin Point Laboratories Limited's Irbesartan Exports?
Caplin Point Laboratories Limited's average Irbesartan shipment value is $50.0K per consignment, based on 106 shipments totaling $5.3M. The largest destination is GAUTEMALA (36.1% of Caplin Point Laboratories Limited's Irbesartan exports).
How Does Caplin Point Laboratories Limited Compare to Other Indian Irbesartan Exporters?
Caplin Point Laboratories Limited ranks #3 among 123 Indian Irbesartan exporters with a 5.0% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($10.8M), MACLEODS PHARMACEUTICALS LTD ($8.9M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($8.3M). Caplin Point Laboratories Limited processed 106 shipments to 9 destination countries.
What Irbesartan Formulations Does Caplin Point Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| IRBESARTAN TABLETS USP 300MG | $1.2M | 35 |
| IRBESARTAN TABLETS USP 150MG | $419.6K | 15 |
| IRBESARTAN AND HYDROCHLOROTHIAZIDE TABLE | $341.9K | 12 |
| IRBESARTAN AND HYDROCHLOROTHIAZIDE TABLETS USP 300MG/25MG | $197.0K | 7 |
| IRBESARTAN TABLETS USP 150 MG | $196.0K | 6 |
| IRBESARTAN TABLETS USP 300 MG | $168.1K | 5 |
| IRBESARTAN AND HYDROCHLOROTHIAZIDE TABLETS USP 150MG/12.5MG | $152.8K | 8 |
| IRBESARTAN TABLETS USP 300MGNOS | $117.2K | 6 |
| IRBESARTAN AND HYDROCHLOROTHIAZIDE TABLETS USP 150MG/12.5mg | $50.0K | 1 |
| IRBESARTAN AND HYDROCHLOROTHIAZIDE TABLETS USP 300 MG / 25 MG | $50.0K | 1 |
Caplin Point Laboratories Limited exports 20 distinct Irbesartan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is IRBESARTAN TABLETS USP 300MG with 35 shipments worth $1.2M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Caplin Point Laboratories Limited Compare to Nearest Irbesartan Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $8.3M | 298 | 13 | $28.0K |
| 5 | ALEMBIC PHARMACEUTICALS LIMITED | $7.6M | 189 | 2 | $40.4K |
| 3 | CAPLIN POINT LABORATORIES LIMITED ★ | $5.3M | 106 | 9 | $50.0K |
| 6 | MACLEODS PHARMACEUTICALS LIMITED | $3.6M | 89 | 7 | $40.4K |
| 7 | AUROBINDO PHARMA LTD | $2.7M | 251 | 4 | $10.7K |
Caplin Point Laboratories Limited ranks #3 among 123 Indian Irbesartan exporters. Average shipment value of $50.0K compared to the market average of $473.0K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and ALEMBIC PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Irbesartan Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 284 | 10.6% |
| SAHAR AIR | 197 | 7.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 170 | 6.4% |
| JNPT/ NHAVA SHEVA SEA | 147 | 5.5% |
| DELHI AIR | 135 | 5.1% |
| DELHI AIR CARGO ACC (INDEL4) | 133 | 5.0% |
| JNPT | 129 | 4.8% |
| MUNDRA SEA (INMUN1) | 108 | 4.0% |
What Other Cardiovascular Products Does Caplin Point Laboratories Limited Export?
Caplin Point Laboratories Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Caplin Point Laboratories Limited's Irbesartan Exports
The global pharmaceutical export landscape is currently navigating several geopolitical challenges that directly impact companies like Caplin Point.
The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing maritime carriers to suspend bookings and reroute vessels around the Cape of Good Hope. This has resulted in elongated lead times and increased shipping costs, disproportionately affecting time-sensitive pharmaceutical shipments. Freight charges have surged, with transport costs doubling and additional surcharges ranging from $4,000 to $8,000 per shipment. Such disruptions pose significant risks to the timely delivery of pharmaceuticals, especially those requiring stringent cold-chain logistics. (pharmaceuticalcommerce.com)
In the United States, recent tariff implementations have introduced further complexities. The U.S. administration has imposed broad tariffs on imports from over 60 countries, including India, with rates reaching up to 39%. These tariffs affect a substantial portion of Indian exports to the U.S., including pharmaceuticals, potentially leading to increased costs and competitive disadvantages for Indian exporters. (apnews.com)
The European Union's regulatory landscape is also evolving, with stricter compliance requirements under directives like the Falsified Medicines Directive. Indian pharmaceutical companies must invest in advanced serialization and traceability systems to meet these standards, ensuring continued access to the lucrative EU market.
For Caplin Point, these geopolitical and regulatory developments necessitate strategic adaptations. Diversifying export markets, enhancing supply chain resilience, and investing in compliance infrastructure are critical to mitigating risks and sustaining growth in this volatile environment.
Caplin Point Laboratories Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, particularly from agencies like the U.S. FDA and the European Medicines Agency. Compliance with Good Manufacturing Practices (GMP) and other quality standards is imperative for market access.
Caplin Point has proactively addressed these requirements. The company's subsidiary, Caplin Steriles Limited (CSL), has secured an EU GMP renewal and successfully passed audits by regulatory bodies such as the Saudi FDA. These achievements underscore Caplin Point's commitment to maintaining high-quality standards and ensuring compliance with international regulations. (whalesbook.com)
However, the broader Indian pharmaceutical sector faces challenges related to quality and compliance. The U.S. FDA conducted over 200 inspections in India in 2023, with plans to increase this number in subsequent years. Instances of substandard products have led to increased scrutiny, emphasizing the need for continuous quality improvements. (fact.net.in)
For Caplin Point, ongoing investment in quality assurance systems, employee training, and infrastructure upgrades is essential to navigate the evolving regulatory landscape and maintain its competitive edge.
About Caplin Point Laboratories Limited
Caplin Point Laboratories Limited exports 55 products worth $174.5M. Beyond Irbesartan, top products include Ibuprofen, Diclofenac, Clotrimazole, Potassium, Vitamin. View the complete Caplin Point Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Irbesartan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Irbesartan shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Caplin Point Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 106 individual customs records matching Caplin Point Laboratories Limited exporting Irbesartan, covering 20 formulations to 10 countries via 19 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 68+ countries, 366+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Irbesartan Export Data from Caplin Point Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Caplin Point Laboratories Limited's Irbesartan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Caplin Point Laboratories Limited
Full Company Profile →
55 products · $174.5M total trade · 20 categories
Irbesartan Stats
Company Overview
Top Products by Caplin Point Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Caplin Point Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Irbesartan. For current shipment-level data, contact TransData Nexus.